Restricted accessResearch articleFirst published online 2013-03
Cultivation in Human Serum Reduces Adipose Tissue-Derived Mesenchymal Stromal Cell Adhesion to Laminin and Endothelium and Reduces Capillary Entrapment
The increasing use of mesenchymal stromal cells (MSC) in clinical cellular therapy requires a safe and controlled production process compliant with Good Manufacturing Practice guidelines. Pooled blood group AB human serum (HS) has been used to replace fetal bovine serum (FBS), critically rated by the regulatory agencies, since it can support the expansion of adipose tissue-derived mesenchymal stromal cells (ASC). However, it remains unknown whether the choice of serum affects application-relevant characteristics of ASC. A microarray-based screen has revealed differentially expressed adhesion and extracellular matrix-associated molecules in HS- and FBS-ASC. Since cell therapy relies on the cells' efficacy to home and engraft, HS- and FBS-ASC were compared by analyzing adhesion, migration, and transmigration as well as short-term homing in vivo. HS-cultivated ASC demonstrated a higher adhesion to plastic, but reduced adhesion to extracellular matrix molecules, that is, laminin, and to endothelial cells both under static and flow conditions. Migration and transmigration assays confirmed the attraction of ASC by the tumor conditioned medium irrespective of the supplement. Coinjecting differently labeled HS- and FBS-ASC into nonobese diabetic, severe combined immunodeficiency mice revealed reduced numbers of HS-ASC in lungs and liver. This has been interpreted as reduced capillary entrapment. Our data indicate that varying the serum supplement may alter application-relevant characteristics of ASC, such as adhesion, as well as lung entrapment after infusion. Appropriate injury models and further molecular analyses are required to provide mechanistic insight into the differential effects of HS versus FBS on ASC cultures.
TolarJ, Le BlancK, KeatingA, BlazarBR. 2010. Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells, 28:1446–1455.
3.
HorwitzEM, DominiciM. 2008. How do mesenchymal stromal cells exert their therapeutic benefit?Cytotherapy, 10:771–774.
4.
KernS, EichlerH, StoeveJ, KluterH, BiebackK. 2006. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells, 24:1294–1301.
5.
RaJCet al.2011. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev, 20:1297–1308.
6.
SensebeL, BourinP. 2008. Producing MSC according GMP: process and controls. Biomed Mater Eng, 18:173–177.
7.
BiebackK, KinzebachS, KaragianniM. 2011. Translating research into clinical scale manufacturing of mesenchymal stromal cells. Stem Cells193519. [Epub ahead of print]10.4061/2010/193519
SundinM, RingdenO, SundbergB, NavaS, GotherstromC, Le BlancK. 2007. No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica, 92:1208–1215.
10.
TontiGA, MannelloF. 2008. From bone marrow to therapeutic applications: different behaviour and genetic/epigenetic stability during mesenchymal stem cell expansion in autologous and foetal bovine sera?Int J Dev Biol, 52:1023–1032.
11.
HeiskanenAet al.2007. N-glycolylneuraminic acid xenoantigen contamination of human embryonic and mesenchymal stem cells is substantially reversible. Stem Cells, 25:197–202.
12.
SpeesJL, GregoryCA, SinghH, TuckerHA, PeisterA, LynchPJ, HsuSC, SmithJ, ProckopDJ. 2004. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther, 9:747–756.
13.
HorwitzEM, ProckopDJ, GordonPL, KooWW, FitzpatrickLA, NeelMD, McCarvilleME, OrchardPJ, PyeritzRE, BrennerMK. 2001. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood, 97:1227–1231.
14.
KocaoemerA, KernS, KluterH, BiebackK. 2007. Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells, 25:1270–1278.
15.
BiebackK, HaVA, HeckerA, GrasslM, KinzebachS, SolzH, StichtC, KluterH, BugertP. 2010. Altered gene expression in human adipose stem cells cultured with fetal bovine serum compared to human supplements. Tissue Eng Part A, 16:3467–3484.
16.
BiebackK, HeckerA, SchlechterT, HofmannI, BrousosN, RedmerT, BesserD, KlueterH, MüllerAM, BeckerM. 2012. Replicative aging and differentiation potential of human adipose tissue-derived mesenchymal stromal cells expanded in pooled human or fetal bovine serum. Cytotherapy, 14:570–583.
17.
DeakE, SeifriedE, HenschlerR. 2010. Homing pathways of mesenchymal stromal cells (MSCs) and their role in clinical applications. Int Rev Immunol, 29:514–529.
18.
SpaethE, KloppA, DembinskiJ, AndreeffM, MariniF. 2008. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther, 15:730–738.
19.
KarpJM, Leng TeoGS. 2009. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell, 4:206–216.
FoxJM, ChamberlainG, AshtonBA, MiddletonJ. 2007. Recent advances into the understanding of mesenchymal stem cell trafficking. Br J Haematol, 137:491–502.
22.
DochevaD, PopovC, MutschlerW, SchiekerM. 2007. Human mesenchymal stem cells in contact with their environment: surface characteristics and the integrin system. J Cell Mol Med, 11:21–38.
23.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniF, KrauseD, DeansR, KeatingA, ProckopD, HorwitzE. 2006. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
24.
BaudinB, BruneelA, BosselutN, VaubourdolleM. 2007. A protocol for isolation and culture of human umbilical vein endothelial cells. Nat Protoc, 2:481–485.
25.
BurridgeK, TurnerCE, RomerLH. 1992. Tyrosine phosphorylation of paxillin and pp125FAK accompanies cell adhesion to extracellular matrix: a role in cytoskeletal assembly. J Cell Biol, 119:893–903.
26.
StudenyM, MariniFC, ChamplinRE, ZompettaC, FidlerIJ, AndreeffM. 2002. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res, 62:3603–3608.
27.
LinSY, YangJ, EverettAD, ClevengerCV, KoneruM, MishraPJ, KamenB, BanerjeeD, GlodJ. 2008. The isolation of novel mesenchymal stromal cell chemotactic factors from the conditioned medium of tumor cells. Exp Cell Res, 314:3107–3117.
28.
GiaeverI, KeeseCR. 1984. Monitoring fibroblast behavior in tissue culture with an applied electric field. Proc Natl Acad Sci U S A, 81:3761–3764.
29.
AngstmannM, BrinkmannI, BiebackK, BreitkreutzD, MaerckerC. 2011. Monitoring human mesenchymal stromal cell differentiation by electrochemical impedance sensing. Cytotherapy, 13:1074–1089.
30.
RusterB, GottigS, LudwigRJ, BistrianR, MullerS, SeifriedE, GilleJ, HenschlerR. 2006. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood, 108:3938–3944.
31.
WynnRF, HartCA, Corradi-PeriniC, O'NeillL, EvansCA, WraithJE, FairbairnLJ, BellantuonoI. 2004. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood, 104:2643–2645.
32.
ShiM, LiJ, LiaoL, ChenB, LiB, ChenL, JiaH, ZhaoRC. 2007. Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. Haematologica, 92:897–904.
33.
KyriakouC, RabinN, PizzeyA, NathwaniA, YongK. 2008. Factors that influence short-term homing of human bone marrow-derived mesenchymal stem cells in a xenogeneic animal model. Haematologica, 93:1457–1465.
34.
LiuZJ, ZhugeY, VelazquezOC. 2009. Trafficking and differentiation of mesenchymal stem cells. J Cell Biochem, 106:984–991.
35.
SemonJA, NagyLH, LlamasCB, TuckerHA, LeeRH, ProckopDJ. 2010. Integrin expression and integrin-mediated adhesion in vitro of human multipotent stromal cells (MSCs) to endothelial cells from various blood vessels. Cell Tissue Res, 341:147–158.
36.
ChoHH, KyoungKM, SeoMJ, KimYJ, BaeYC, JungJS. 2006. Overexpression of CXCR4 increases migration and proliferation of human adipose tissue stromal cells. Stem Cells Dev, 15:853–864.
37.
FurlaniDet al.2009. Is the intravascular administration of mesenchymal stem cells safe? Mesenchymal stem cells and intravital microscopy. Microvasc Res, 77:370–376.
38.
TomaC, WagnerWR, BowryS, SchwartzA, VillanuevaF. 2009. Fate of culture-expanded mesenchymal stem cells in the microvasculature: in vivo observations of cell kinetics. Circ Res, 104:398–402.
39.
LeeRH, PulinAA, SeoMJ, KotaDJ, YlostaloJ, LarsonBL, Semprun-PrietoL, DelafontaineP, ProckopDJ. 2009. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell, 5:54–63.
40.
DevineSM, CobbsC, JenningsM, BartholomewA, HoffmanR. 2003. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood, 101:2999–3001.
41.
FrancoisSet al.2006. Local irradiation not only induces homing of human mesenchymal stem cells at exposed sites but promotes their widespread engraftment to multiple organs: a study of their quantitative distribution after irradiation damage. Stem Cells, 24:1020–1029.
42.
LeyK, LaudannaC, CybulskyMI, NoursharghS. 2007. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol, 7:678–689.
43.
SteingenC, BrenigF, BaumgartnerL, SchmidtJ, SchmidtA, BlochW. 2008. Characterization of key mechanisms in transmigration and invasion of mesenchymal stem cells. J Mol Cell Cardiol, 44:1072–1084.
44.
MenonLG, PicinichS, KoneruR, GaoH, LinSY, KoneruM, Mayer-KuckukP, GlodJ, BanerjeeD. 2007. Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells. Stem Cells, 25:520–528.
45.
MaijenburgMW, NoortWA, KleijerM, KompierCJ, WeijerK, van BuulJD, van der SchootCE, VoermansC. 2010. Cell cycle and tissue of origin contribute to the migratory behaviour of human fetal and adult mesenchymal stromal cells. Br J Haematol, 148:428–440.
46.
BaekSJ, KangSK, RaJC. 2011. In vitro migration capacity of human adipose tissue-derived mesenchymal stem cells reflects their expression of receptors for chemokines and growth factors. Exp Mol Med, 43:596–603.
47.
OzakiY, NishimuraM, SekiyaK, SuehiroF, KanawaM, NikawaH, HamadaT, KatoY. 2007. Comprehensive analysis of chemotactic factors for bone marrow mesenchymal stem cells. Stem Cells Dev, 16:119–129.
48.
ChamberlainG, RotA, AshtonB, MiddletonJ. 2008. Chemokine receptors on human and murine mesenchymal stem cells. Rheumatology, 47:Ii61–Ii62.
49.
HonczarenkoM, LeY, SwierkowskiM, GhiranI, GlodekAM, SilbersteinLE. 2006. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells, 24:1030–1041.
50.
CoralliniF, SecchieroP, BeltramiAP, CesselliD, PuppatoE, FerrariR, BeltramiCA, ZauliG. 2010. TNF-alpha modulates the migratory response of mesenchymal stem cells to TRAIL. Cell Mol Life Sci, 67:1307–1314.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
